A brief pulse of rapamycin before the onset of aging extended lifespan by triggering lasting increases in autophagy. The authors called this phenomenon "rapamycin memory." Elevated autophagy was accompanied by increased levels of LManV and lysozyme in fruit flies, in intestinal enterocytes in female fly models, and its Man2B1 homologue in mice. In mice, a 3-month treatment in early adulthood had the same effect as chronic treatment, even 6 months after rapamycin was withdrawn. In the study published in the Aug. 29, 2022, issue of Nature Aging and led by researchers at the Max Planck Institute, scientists showed that the lifespan-increasing response to rapamycin treatment decreased with the age at which treatment is started. Read More
Microsomal prostaglandin E2 synthase-1 (mPGES1) is a molecule belonging to the MAPEG superfamily and is involved in the conversion of PGH2 to excess PGE2 associated with pain and inflammation. Gesynta Pharma AB presented first data on the mPGES1 inhibitor GS-248 for the treatment of pain and inflammation. In their experiments, GS-248 demonstrated a human whole-blood assay (hWBA) IC50 of 0.4 nM, and hWBA activity about 1000-fold more potent than that of celecoxib. No cross reactivity was observed with COX1 or COX2. Moreover, the compound showed IC50 values for human, dog, rat/mouse and minipig mPGES1 of 2.5, 1.3, > 1000 and 23 nM, respectively. Read More
Beijing Guohong Biomedical Technology Co. Ltd. has presented new inhibitors of proto-oncogene tyrosine-protein kinase Src, hepatocyte growth factor receptor and more. Read More
Ocean Biomedical Inc. reported the discovery of bispecific antibodies that target chitinase-3-like protein 1 and immune checkpoint inhibitors. Read More
Arcutis Biotherapeutics Inc. has entered into an agreement to acquire Ducentis Biotherapeutics Inc., a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Read More
Purnovate Inc., a subsidiary of Adial Pharmaceuticals Inc., has obtained promising in vivo data from a study in mice treated with PNV-6005 as a potential treatment for inflammatory bowel disease (IBD). Read More
Avalo Therapeutics Inc.'s human B and T lymphocyte attenuator (BTLA) agonist fusion protein, AVTX-008, has entered IND-enabling studies, with the company evaluating a number of immune dysregulation disorders to pursue. Read More
Researchers from Centre National de la Recherche Scientifique and affiliated organizations presented the discovery and preclinical identification of novel inhibitors of metallo-beta-lactamases (MBLs). Synthesis and optimization of novel broad-spectrum inhibitors against most relevant MBLs, such as VIM-type enzymes and NDM-1, led to the identification of JMV-7061 as the lead from the series. Read More
Cerebral creatine (Cr) deficiency syndromes are caused by AGAT, GAMT or SLC6A8 deficiencies that may cause severe neurodevelopmental delay and intellectual disability. Read More
Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders. Read More
Sphingosine 1-phosphate (S1P) is a pleiotropic mediator involved in a variety of cellular functions. It is a product of cell membrane sphingolipid catabolism as it is generated from sphingosine intracellularly by sphingosine kinases 1 and 2 (SphK1 and SphK2), and it is exported from cells by spinster homolog 2 (Spns2) or major facilitator superfamily 2b (Mfsd2b). Read More
